Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV005068410 | SCV005706831 | uncertain significance | not provided | 2024-06-29 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with phenylalanine, which is neutral and non-polar, at codon 682 of the SLC4A1 protein (p.Ser682Phe). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SLC4A1-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC4A1 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV005269128 | SCV005946288 | uncertain significance | Inborn genetic diseases | 2025-03-06 | criteria provided, single submitter | clinical testing | The c.2045C>T (p.S682F) alteration is located in exon 16 (coding exon 15) of the SLC4A1 gene. This alteration results from a C to T substitution at nucleotide position 2045, causing the serine (S) at amino acid position 682 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |